2025 · 1st Quarter (Jan 1 - Mar 31)
Filed by CROSSROADS STRATEGIES, LLC.
Open official filingSource-reported fields
Literal source text
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, mental health, opioid abuse, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, plasma therapy, step therapy, and PBM reform; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; Inflation Reduction Act of 2022 (P.L.117-169) implementation; S.891, Bipartisan Health Care Act.
Literal federal measure citations: S.891
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.
H.R.1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (P.L.119-4); H.Con.Res.14, FY2025 Budget Resolution; FY2025 Budget Reconciliation Process; all bio-pharmaceutical related provisions.
Literal federal measure citations: H.R.1968, H.Con.Res.14
Issues related to tax reform. Tax issues related to Inflation Reduction Act of 2022 (P.L.117-169) implementation. Issues related to R&D tax credit. Issues related to orphan drug tax credit.
Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.
Issues related to pharmaceutical IP, supply chain, and tariffs.
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.
